口服和静注昂丹色曲(ondansetron,枢复宁)的安全性已在全世界的7000多名癌症病人临床试验中进行了评估.在接受一日化疗的成年病人中静脉注射本品的不良反应发生率为45%,用甲氧氯普胺的病人则为59%;用本品的病人头痛发生率为17%,用甲氧氯普胺的病人则为10%.报道有腹泻症状的前者为15%,后者为29%.一次静注8mg或32mg,或3次静注0.15mg/kg所引起的不良反应的类型和发生率相似,如头痛发生率一次使用32mg The safety of oral and intravenous ondansetron has been evaluated in more than 7,000 clinical trials of cancer patients around the world. Intravenous injection of this product into adult patients receiving first-day chemotherapy The incidence of the reaction was 45%, with metoclopramide 59% of patients; the incidence of headache in patients with this product was 17%, metoclopramide 10% of patients reported diarrhea The former was 15%, the latter was 29% .Animal intravenous injection of 8mg or 32mg, or 3 intravenous injection of 0.15mg / kg caused the type of adverse reactions and the incidence of similar, such as the incidence of headache once using 32mg